Albany, NY -- (SBWIRE) -- 03/05/2018 -- Meningitis is referred to as the inflammation (swelling) of meninges or membranes that cover the brain and the spinal cord. People of any age can be affected by the meningitis disease. The most common cause of meningitis is bacteria or viruses. However, microorganisms other than bacteria or viruses and certain medications (for example, amoxicillin, azathioprine, or methotrexate) or certain illnesses may also lead to meningitis. Fever, irritability, skin rashes, headache, drowsiness, and fits (seizures) are some of the most common signs and symptoms of meningitis. Signs and symptoms of infant meningitis might differ. They include jaundice, weak suck, and stiffness of the body and neck. Some of the major complications of meningitis are brain damage, hearing loss, epilepsy, vision loss, bone and joint problems, and loss of limbs (amputation). Patients suffering from meningitis can be diagnosed by their medical history, physical examination, and certain diagnostic tests. Meningitis diagnostic tests include laboratory tests and imaging studies that are primarily used to detect meningitis infection.
The global Meningitis Diagnostics Testing Market is expanding significantly, owing to increased chances of infection led by increase in the life expectancy of people across the globe. A driving factor for the meningitis diagnostic testing market is rising initiatives by governments and disease foundations. For instance, GAVI has taken an initiative to save children’s lives and protect public health through the widespread use of diagnostic tests. Growth of the meningitis diagnostic testing market can also be attributed to the rise in cross-country travel and increase in the number of road accidents.
Request to View Brochure of Report -
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1973
The global meningitis diagnostic testing market can be segmented on the basis of type, source of infection, end-user, and region. Types of meningitis diagnostic tests include complete blood count test, blood culture test, lumbar puncture (spinal tap) test, imaging tests (computed tomography (CT) scan and magnetic resonance imaging (MRI)), and others. Blood culture tests help identify the bacteria in the blood. MRI or CT scan of the head show swelling or inflammation of meninges. X-ray or CT scan of the chest may also show the infection and help diagnose the meningitis disease. Spinal tap or lumbar puncture test is employed to identify increased pressure on the central nervous system (CNS) and inflammation or presence of bacteria in the spinal fluid.
In terms of end-user, the meningitis diagnostic testing market can be segmented into hospitals, diagnostic laboratories, and others. In terms of revenue, the hospitals segment held a significant share of the meningitis diagnostic testing market in 2016.
Request to View ToC of Report -
https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=1973
In terms of region, the global meningitis diagnostic testing market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the leading market for meningitis diagnostic testing, followed by Europe, Asia Pacific, Latin America, and Middle East & Africa. In terms of revenue, the U.S. holds a major share of the meningitis diagnostic testing market in North America. The market in Europe is expanding rapidly, due to increase in the patient population, especially in Germany. Moreover, the market in Asia Pacific and Latin America is projected to expand significantly in the near future. Developing economies such as China and Japan are projected to contribute to growth of the market in APAC between 2017 and 2025, due to better health care infrastructure, economic growth, increase in the number of insurance payers, growth of the private health care sector, and increasing awareness through awareness programs.
Key players operating in the global meningitis diagnostic testing market are Abbott Laboratories, Inc., Affymetrix, Inc., Bio-Rad Laboratories, Inc., Diamedix Corporation (a subsidiary of IVAX Diagnostics, Inc.), DiaSorin S.p.A., Fujirebio Diagnostics, Inc., Gen-Probe, Inc., Novartis Diagnostics, XCyton Diagnostics Limited, BioFire Diagnostics, HiberGene Diagnostics, and Diagenode Diagnostics.
Enquiry for discount on this report -
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1973